Watch for FDA action on the pending BLAs for AVT05, AVT06, AVT03, and AVT16/AVT80, which could serve as additional catalysts. The VAI classification and DSM2 approval significantly reduce manufacturing overhang, potentially accelerating partnership and revenue timelines for the pipeline.
Price Chart
Executive Summary
Alvotech announced FDA approval of a second drug substance manufacturing suite (DSM2) at its Reykjavik facility for SIMLANDI (AVT02), its biosimilar to Humira, effectively doubling U.S. commercial supply capacity. The approval follows the FDA's July 2026 inspection closure with a Voluntary Action Indicated (VAI) classification, and Alvotech expects the FDA to now act on pending BLAs for AVT05, AVT06, AVT03, and AVT16/AVT80. This is a positive regulatory milestone that de-risks the manufacturing site and opens a path for pipeline product approvals.
Key Facts
- FDA approved a supplement to the BLA for AVT02 (SIMLANDI) enabling drug substance manufacture in a second production suite (DSM2) at the Reykjavik facility.
- DSM2 effectively doubles the drug substance manufacturing capacity available to support U.S. supply of SIMLANDI.
- Approval confirms resolution of FDA inspection-related matters at the Reykjavik site, following a July 2026 inspection closure with VAI classification.
- Alvotech expects the FDA to be able to act on pending BLAs for AVT05 (golimumab), AVT06 (aflibercept), AVT03 (denosumab), and AVT16/AVT80 (vedolizumab) according to their goal dates.
- DSM2 is already approved for commercial drug substance manufacture for European markets for AVT02, AVT03, and AVT05.
Financial Impact
Doubles U.S. manufacturing capacity for SIMLANDI, Alvotech's biosimilar to Humira, which is commercialized in the U.S. by Teva Pharmaceuticals. No specific revenue or cost figures provided.
Risk Factors
- Each pending BLA remains subject to individual FDA review and regulatory decision — no guarantee of approval.
- SIMLANDI faces competition from other Humira biosimilars in the U.S. market.
- Forward-looking statements regarding pipeline approvals and commercial timelines are inherently uncertain.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001171843-26-006383 |
| Exhibit: exh_991.htm | 0001171843-26-006383 |
| Document: 0001171843-26-006383-index-headers.html | 0001171843-26-006383 |
| Document: 0001171843-26-006383-index.html | 0001171843-26-006383 |
| Document: 0001171843-26-006383.txt | 0001171843-26-006383 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 6d ago | 6-K | $5.12 | awaiting T+20 | — | $4.62 (−9.77%) |
Oct 14, 2026 12d ago | 6-K | $5.17 | awaiting T+20 | — | $4.62 (−10.64%) |
Oct 7, 2026 19d ago | 6-K | $5.85 | awaiting T+20 | — | $4.62 (−21.03%) |
Oct 5, 2026 21d ago | 6-K | $6.11 | awaiting T+20 | — | $4.62 (−24.39%) |
Oct 5, 2026 21d ago | Press Release | $6.11 | awaiting T+20 | — | $4.62 (−24.39%) |
Aug 31, 2026 8w ago | 6-K | $5.19 $5.92 | ▲ +14.07% | ▲ +14.44% | $4.62 (−10.98%) |
Aug 21, 2026 9w ago | 6-K | $4.43 $5.88 | ▲ +32.73% | ▲ +31.72% | $4.62 (+4.29%) |
Aug 19, 2026 9w ago | Press Release | $4.27 $5.87 | ▼ −37.47% | ▼ −37.59% | $4.62 (−8.20%) |
Jul 29, 2026 12w ago | 6-K | $3.53 $4.91 | ▲ +39.09% | ▲ +34.07% | $4.62 (+30.88%) |
Jul 3, 2026 16w ago | Press Release | $3.46 $4.12 | ▲ +19.08% | ▲ +19.64% | $4.62 (+33.53%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers